Litcius/Paper detail

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial

Patrizia Froesch, Michael Mark, Sacha I. Rothschild, Qiyu Li, Gilles Godar, Corinne Rusterholz, Elisabeth Oppliger Leibundgut, Sabine Schmid, Ilaria Colombo, Yannis Metaxas, David König, Cristiana Sessa, Oliver Gautschi, Martin Früh

2021Lung Cancer21 citationsDOI

Topics & Concepts

PemetrexedMedicineKRASInternal medicineOncologyCohortLung cancerRashnon-small cell lung cancer (NSCLC)Progressive diseaseGastroenterologyCancerChemotherapyCisplatinColorectal cancerA549 cellLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysLung Cancer Diagnosis and Treatment
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial | Litcius